RNAi modulation of placental sFLT1 for the treatment of preeclampsia

Nature Biotechnology

Volumn 36, Issue 12, 2018, Pages 1164-1173

  Turanov, Anton A ^a   Lo, Agnes ^b,c   Hassler, Matthew R ^a   Makris, Angela ^d,e,f   Ashar Patel, Ami ^a   Alterman, Julia F ^a   Coles, Andrew H ^a   Haraszti, Reka A ^a   Roux, Loic ^a   Godinho, Bruno M D C ^a   Echeverria, Dimas ^a   Pears, Suzanne ^d   Iliopoulos, Jim ^e   Shanmugalingam, Renuka ^d,e,f   Ogle, Robert ^g   Zsengeller, Zsuzsanna K ^b,c   Hennessy, Annemarie ^d,e   Karumanchi, S Ananth ^b,c,h   Moore, Melissa J ^a,i   Khvorova, Anastasia ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HEART RESEARCH INSTITUTE   (Australia)

^e UNIVERSITY OF WESTERN SYDNEY   (Australia)

^f LIVERPOOL HOSPITAL   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ MODERNA THERAPEUTICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL MODIFICATION; GENE EXPRESSION; MAMMALS; MODULATION; NUCLEIC ACIDS; RNA;

CHEMICAL STABILIZATION; CLINICAL MANIFESTATION; CLINICAL SIGNS; HYDROPHOBIC MODIFICATION; NON-HUMAN PRIMATE; OVER-EXPRESSION; SHORT INTERFERING RNA; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

PATIENT TREATMENT;

MESSENGER RNA; SMALL INTERFERING RNA; VASCULOTROPIN RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; BIOACCUMULATION; CONTROLLED STUDY; EXON; FEMALE; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HYDROPHOBICITY; HYPERTENSION; INTRON; MOUSE; NONHUMAN; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; RNA INTERFERENCE; SINGLE DRUG DOSE;

EID: 85058728860     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.4297     Document Type: Article

References (69)

1. Stevens, W. et al. Short-term costs of preeclampsia to the United States health care system. Am. J. Obstet. Gynecol. 217, 237–248.e216 (2017).
2. Maynard, S.E. et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649–658 (2003).
3. Levine, R.J. et al. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672–683 (2004).
4. Heydarian, M. et al. Novel splice variants of sFlt1 are upregulated in preeclampsia. Placenta 30, 250–255 (2009).
5. Young, B.C., Levine, R.J. & Karumanchi, S.A. Pathogenesis of preeclampsia. Annu. Rev. Pathol. 5, 173–192 (2010).
6. Aubuchon, M., Schulz, L.C. & Schust, D.J. Preeclampsia: animal models for a human cure. Proc. Natl. Acad. Sci. USA 108, 1197–1198 (2011).
7. Chaiworapongsa, T. et al. Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Am. J. Obstet. Gynecol. 190, 1541–1547; discussion 1547–1550 (2004).
8. Lu, F. et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am. J. Obstet. Gynecol. 196, 396 e391–397; discussion 396 e397 (2007).
9. Ahmad, S. & Ahmed, A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ. Res. 95, 884–891 (2004).
10. Redman, C.W. & Sargent, I.L. Latest advances in understanding preeclampsia. Science 308, 1592–1594 (2005).
11. Vorlová, S. et al. Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic polyA activation. Mol. Cell 43, 927–939 (2011).
12. Kendall, R.L. & Thomas, K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc. Natl. Acad. Sci. USA 90, 10705–10709 (1993).
13. Bujold, E. et al. Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. J. Matern. Fetal Neonatal Med. 18, 9–16 (2005).
14. Zeisler, H. et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N. Engl. J. Med. 374, 13–22 (2016).
15. Sunderji, S. et al. Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am. J. Obstet. Gynecol. 202, 40 e41–47 (2010).
16. Rana, S. et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 125, 911–919 (2012).
17. Chaiworapongsa, T. et al. Plasma concentrations of angiogenic/anti-angiogenic factors have prognostic value in women presenting with suspected preeclampsia to the obstetrical triage area: a prospective study. J. Matern. Fetal Neonatal Med. 27, 132–144 (2014).
18. Thadhani, R. et al. Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation 124, 940–950 (2011).
19. Thadhani, R. et al. Removal of soluble fms-like tyrosine kinase-1 by dextran sulfate apheresis in preeclampsia. J. Am. Soc. Nephrol. 27, 903–913 (2016).
20. Khvorova, A. & Watts, J.K. The chemical evolution of oligonucleotide therapies of clinical utility. Nat. Biotechnol. 35, 238–248 (2017).
21. Fitzgerald, K. et al. A highly durable RNAi therapeutic inhibitor of PCSK9. N. Engl. J. Med. 376, 41–51 (2017).
22. Khvorova, A. Oligonucleotide therapeutics – a new class of cholesterol-lowering drugs. N. Engl. J. Med. 376, 4–7 (2017).
23. Haraszti, R.A. et al. 5′-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo. Nucleic Acids Res. 45, 7581–7592 (2017).
24. Soutschek, J. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432, 173–178 (2004).
25. Byrne, M. et al. Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. J. Ocul. Pharmacol. Ther. 29, 855–864 (2013).
26. Khan, T. et al. Silencing myostatin using cholesterol-conjugated siRNAs induces muscle growth. Mol. Ther. Nucleic Acids 5, e342 (2016).
27. Hassler, M.R. et al. Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Res. 46, 2185–2196 (2018).
28. Ashar-Patel, A. et al. FLT1 and transcriptome-wide polyadenylation site (PAS) analysis in preeclampsia. Sci. Rep. 7, 12139 (2017).
29. Palmer, K.R. et al. Placental-specific sFLT-1 e15a protein is increased in preeclampsia, antagonizes vascular endothelial growth factor signaling, and has antiangiogenic activity. Hypertension 66, 1251–1259 (2015).
30. Souders, C.A. et al. Circulating levels of sFlt1 splice variants as predictive markers for the development of preeclampsia. Int. J. Mol. Sci. 16, 12436–12453 (2015).
31. Birmingham, A. et al. A protocol for designing siRNAs with high functionality and specificity. Nat. Protoc. 2, 2068–2078 (2007).
32. Anderson, E.M. et al. Experimental validation of the importance of seed complement frequency to siRNA specificity. RNA 14, 853–861 (2008).
33. Khvorova, A., Reynolds, A. & Jayasena, S.D. Functional siRNAs and miRNAs exhibit strand bias. Cell 115, 209–216 (2003).
34. Schwarz, D.S. et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199–208 (2003).
35. Alterman, J.F. et al. Hydrophobically modified siRNAs silence huntingtin mRNA in primary neurons and mouse brain. Mol. Ther. Nucleic Acids 4, e266 (2015).
36. Godinho, B.M.D.C. et al. Pharmacokinetic profiling of conjugated therapeutic oligonucleotides: a high-throughput method based upon serial blood microsampling coupled to peptide nucleic acid hybridization assay. Nucleic Acid Ther. 27, 323–334 (2017).
37. Ly, S. et al. Visualization of self-delivering hydrophobically modified siRNA cellular internalization. Nucleic Acids Res. 45, 15–25 (2017).
38. Wang, S. et al. Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Res. 46, 3579–3594 (2018).
39. Allerson, C.R. et al. Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J. Med. Chem. 48, 901–904 (2005).
40. Sela, S. et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ. Res. 102, 1566–1574 (2008).
41. Holme, A.M., Roland, M.C., Henriksen, T. & Michelsen, T.M. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies. Am. J. Obstet. Gynecol. 215, 782.e781–782.e789 (2016).
42. Rajakumar, A. et al. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension 59, 256–264 (2012).
43. Makris, A. et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int. 71, 977–984 (2007).
44. Amadio, M., Govoni, S. & Pascale, A. Targeting VEGF in eye neovascularization: what’s new?: a comprehensive review on current therapies and oligonucleotide-based interventions under development. Pharmacol. Res. 103, 253–269 (2016).
45. Ambati, B.K. et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature 443, 993–997 (2006).
46. Lertkiatmongkol, P., Liao, D., Mei, H., Hu, Y. & Newman, P.J. Endothelial functions of platelet/endothelial cell adhesion molecule-1 (CD31). Curr. Opin. Hematol. 23, 253–259 (2016).
47. Karumanchi, S.A. Angiogenic factors in preeclampsia: from diagnosis to therapy. Hypertension 67, 1072–1079 (2016).
48. Bergmann, A. et al. Reduction of circulating soluble Flt-1 alleviates preeclampsia-like symptoms in a mouse model. J. Cell. Mol. Med. 14 6B, 1857–1867 (2010).
49. Spradley, F.T. et al. Placental growth factor administration abolishes placental ischemia-induced hypertension. Hypertension 67, 740–747 (2016).
50. Makris, A. et al. Placental growth factor reduces blood pressure in a uteroplacental ischemia model of preeclampsia in nonhuman primates. Hypertension 67, 1263–1272 (2016).
51. Yu, D. et al. Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression. Cell 150, 895–908 (2012).
52. Nair, J.K. et al. Impact of enhanced metabolic stability on pharmacokinetics and pharmacodynamics of GalNAc-siRNA conjugates. Nucleic Acids Res. 45, 10969–10977 (2017).
53. Pasi, K.J. et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N. Engl. J. Med. 377, 819–828 (2017).
54. Matsuda, S. et al. siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes. ACS Chem. Biol. 10, 1181–1187 (2015).
55. Nair, J.K. et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J. Am. Chem. Soc. 136, 16958–16961 (2014).
56. Wolfrum, C. et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat. Biotechnol. 25, 1149–1157 (2007).
57. Krützfeldt, J. et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438, 685–689 (2005).
58. Baerlocher, G.M., Burington, B. & Snyder, D.S. Telomerase inhibitor imetelstat in essential thrombocythemia and myelofibrosis. N. Engl. J. Med. 373, 2580 (2015).
59. Yu, J., Jia, J., Guo, X., Chen, R. & Feng, L. Modulating circulating sFlt1 in an animal model of preeclampsia using PAMAM nanoparticles for siRNA delivery. Placenta 58, 1–8 (2017).
60. Khankin, E.V., Mandala, M., Colton, I., Karumanchi, S.A. & Osol, G. Hemodynamic, vascular, and reproductive impact of FMS-like tyrosine kinase 1 (FLT1) blockade on the uteroplacental circulation during normal mouse pregnancy. Biol. Reprod. 86, 57 (2012).
61. Yu, R.Z. et al. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab. Dispos. 35, 460–468 (2007).
62. Geary, R.S., Norris, D., Yu, R. & Bennett, C.F. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46–51 (2015).
63. Savage, V.M. et al. Scaling of number, size, and metabolic rate of cells with body size in mammals. Proc. Natl. Acad. Sci. USA 104, 4718–4723 (2007).
64. Fan, X. et al. Endometrial VEGF induces placental sFLT1 and leads to pregnancy complications. J. Clin. Invest. 124, 4941–4952 (2014).
65. Anderson, E., Boese, Q., Khvorova, A. & Karpilow, J. Identifying siRNA-induced off-targets by microarray analysis. Methods Mol. Biol. 442, 45–63 (2008).
66. Osborn, M.F. et al. Guanabenz (Wytensin™) selectively enhances uptake and efficacy of hydrophobically modified siRNAs. Nucleic Acids Res. 43, 8664–8672 (2015).
67. Rajakumar, A. et al. Novel soluble Flt-1 isoforms in plasma and cultured placental explants from normotensive pregnant and preeclamptic women. Placenta 30, 25–34 (2009).
68. Coles, A.H. et al. A high-throughput method for direct detection of therapeutic oligonucleotide-induced gene silencing in vivo. Nucleic Acid Ther. 26, 86–92 (2016).
69. Nikan, M. et al. Docosahexaenoic acid conjugation enhances distribution and safety of siRNA upon local administration in mouse brain. Mol. Ther. Nucleic Acids 5, e344 (2016).